• Jiji

  • SHARE

The availability of necessary drugs in Japan may take a hit, as low prices are prompting foreign firms not to seek approval for new drugs in the country, Japanese pharmaceutical industry leader Yasushi Okada said in a recent interview.

“Approvals in Japan are decreasing, and the country is seeing trends of a drug lag,” said Okada, president of the Japan Pharmaceutical Manufacturers Association and chief operating officer of Eisai Co.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)